Literature DB >> 18155649

Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.

Robert A Parise1, Jan H Beumer, Cyrous O Kangani, Julianne L Holleran, Julie L Eiseman, Nicola F Smith, Joseph M Covey, Susan P Perrine, Merrill J Egorin.   

Abstract

2,2-Dimethylbutyrate (DMB) is a potential treatment for thalassemia and hemoglobinopathies. To facilitate pharmacokinetic evaluation of DMB, we developed an LC-MS assay and quantitated DMB in plasma of rats after an oral dose of 500mg/kg. After acetonitrile protein precipitation, DMB and dimethylvaleric acid (DMV) internal standard were derivatized to benzylamides, chromatographed on a Hydro-RP column with acetonitrile, water, and 0.1% formic acid, and detected by electrospray positive-mode ionization mass spectrometry. The assay was accurate (97-107%) and precise (3.4-6.2%) between 100 and 10,000ng/mL. Recovery from plasma was >62%. Plasma freeze-thaw and room temperature stability were acceptable.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18155649      PMCID： PMC2254528          DOI： 10.1016/j.jchromb.2007.12.002

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.205


  25 in total

Review 1.  Pharmacologic modulation of fetal hemoglobin.

Authors:  M H Steinberg; G P Rodgers
Journal:  Medicine (Baltimore)       Date:  2001-09       Impact factor: 1.889

2.  One pot direct synthesis of amides or oxazolines from carboxylic acids using Deoxo-Fluor reagent.

Authors:  Cyrous O Kangani; David E Kelley
Journal:  Tetrahedron Lett       Date:  2005-12-19       Impact factor: 2.415

Review 3.  Beta-thalassemia.

Authors:  Deborah Rund; Eliezer Rachmilewitz
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

4.  The importance of the genetic picture and globin synthesis in determining the clinical and haematological features of thalassaemia intermedia.

Authors:  E Gallo; P Massaro; R Miniero; D David; C Tarella
Journal:  Br J Haematol       Date:  1979-02       Impact factor: 6.998

5.  On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC.

Authors:  P Constantoulakis; G Knitter; G Stamatoyannopoulos
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

6.  Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.

Authors:  M J Egorin; Z M Yuan; D L Sentz; K Plaisance; J L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

7.  Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression.

Authors:  Evangelia Skarpidi; Hua Cao; Birgit Heltweg; Brian F White; Ronald L Marhenke; Manfred Jung; George Stamatoyannopoulos
Journal:  Exp Hematol       Date:  2003-03       Impact factor: 3.084

8.  Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy.

Authors:  T Ikuta; Y W Kan; P S Swerdlow; D V Faller; S P Perrine
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

9.  Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo.

Authors:  Betty S Pace; Gary L White; George J Dover; Michael S Boosalis; Douglas V Faller; Susan P Perrine
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.

Authors:  A F Collins; H A Pearson; P Giardina; K T McDonagh; S W Brusilow; G J Dover
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113
View more
  4 in total

1.  Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.

Authors:  Susan P Perrine; William A Wargin; Michael S Boosalis; Wayne J Wallis; Sally Case; Jeffrey R Keefer; Douglas V Faller; William C Welch; Ronald J Berenson
Journal:  J Clin Pharmacol       Date:  2011-03-21       Impact factor: 3.126

2.  New method for GC/FID and GC-C-IRMS analysis of plasma free fatty acid concentration and isotopic enrichment.

Authors:  Cyrous O Kangani; David E Kelley; James P Delany
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-08-19       Impact factor: 3.205

3.  Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties.

Authors:  Michele Biagioli; Daniela Capobianco; Adriana Carino; Silvia Marchianò; Chiara Fiorucci; Patrizia Ricci; Eleonora Distrutti; Stefano Fiorucci
Journal:  Nutrients       Date:  2019-02-02       Impact factor: 5.717

4.  Butyrate histone deacetylase inhibitors.

Authors:  Kosta Steliou; Michael S Boosalis; Susan P Perrine; José Sangerman; Douglas V Faller
Journal:  Biores Open Access       Date:  2012-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.